TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07569926: Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET I

Sponsor: Blue Earth Diagnostics · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 142 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$11,827,200

Rescue Site Savings

+$7,798,560

Unlock Full NCT07569926 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07569926 Rescue Dossier →